Soojj
2021-08-04
Wow
Pfizer hikes 2021 outlook after vaccine boosts sales, profit<blockquote>疫苗提振销售和利润后辉瑞上调2021年展望</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":807705352,"tweetId":"807705352","gmtCreate":1628054926476,"gmtModify":1633753981927,"author":{"id":3582029553166690,"idStr":"3582029553166690","authorId":3582029553166690,"authorIdStr":"3582029553166690","name":"Soojj","avatar":"https://static.tigerbbs.com/2c7b0e3654b1b442172ea81a7188cb95","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/807705352","repostId":1156524625,"repostType":4,"repost":{"id":"1156524625","kind":"news","pubTimestamp":1628053893,"share":"https://www.laohu8.com/m/news/1156524625?lang=zh_CN&edition=full","pubTime":"2021-08-04 13:11","market":"us","language":"en","title":"Pfizer hikes 2021 outlook after vaccine boosts sales, profit<blockquote>疫苗提振销售和利润后辉瑞上调2021年展望</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156524625","media":"Business Hala","summary":"Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter ","content":"<p>Strong sales of its COVID-19 vaccine and other drugs helped<b> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.</p><p><blockquote>其COVID-19疫苗和其他药物的强劲销售有所帮助<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>第二季度营收增长近一倍，利润增长59%，超出华尔街预期。</blockquote></p><p> Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.</p><p><blockquote>其COVID-19疫苗和其他药物的强劲销售帮助辉瑞第二季度收入增长了近一倍，利润增长至59%，超出了华尔街的预期，并帮助这家制药巨头展望2021年。帮助快速提高了销售额和利润预测。</blockquote></p><p> Amid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.</p><p><blockquote>在日益严重的冠状病毒大流行中，COVID-19疫苗成为辉瑞最畅销的疫苗，创造了其近一半的收入——78.4亿美元来自直接销售和与其合作伙伴德国BioNTech的收入分成。</blockquote></p><p> Pfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US</p><p><blockquote>辉瑞目前预测，今年两剂疫苗的收入将达到335亿美元，其已签约在年底前提供21亿剂疫苗。这还不包括上周签署的向美国额外提供2亿剂疫苗的合同</blockquote></p><p> The New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.</p><p><blockquote>这家纽约公司周三透露，正在进行的一项在第二剂疫苗接种六个月后进行的加强注射试验表明，它将老年人和年轻人针对传染性更强的德尔塔变异毒株的抗体水平提高了11倍。增加了五倍多.,与两次给药后的水平相比。该公司还发布的数据显示，接种疫苗六个月后，疫苗在预防严重疾病方面的有效性为97%。</blockquote></p><p> “We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”</p><p><blockquote>首席执行官Albert Boerla在接受采访时表示：“我们绝对相信需要加强剂，第三剂原始疫苗可能就足够了。”尽管如此，辉瑞将在8月份开始在志愿者中测试针对Delta版本的加强剂，因为“利害攸关，你不能冒这个风险。”</blockquote></p><p> Bourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.</p><p><blockquote>Bourla表示，辉瑞已在全球交付了超过10亿剂疫苗，预计今年将生产30亿剂，其中更多将销往中低收入国家。到目前为止，欧洲和美国生产的所有新冠肺炎疫苗的大部分剂量都流向了富裕国家。</blockquote></p><p> By the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.</p><p><blockquote>到9月底，在5至11岁志愿者中进行的试验应产生在该年龄组中获得紧急使用授权所需的安全性和有效性数据，并应使用在6个月至5岁儿童中进行的试验数据。必须遵守。据辉瑞称，很快。</blockquote></p><p> The US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.</p><p><blockquote>美国食品和药物管理局目前正在审查可能导致成人疫苗完全批准的数据，Borla表示，这可能会减少接种疫苗的犹豫。</blockquote></p><p> Second-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.</p><p><blockquote>第二季度净利润为55.6亿美元，合每股98美分，高于34.9亿美元，合每股62美分。</blockquote></p><p> Adjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.</p><p><blockquote>不包括一次性损益的调整后收益为60.8亿美元，即每股1.07美元，明显高于华尔街的97美分。</blockquote></p><p> Its quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.</p><p><blockquote>其季度收入为189.8亿美元，高于去年的98.6亿美元，也超出了预期。</blockquote></p><p> Pfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.</p><p><blockquote>辉瑞股价上涨1.46美元，涨幅3.5%，至43.56美元，接近52周高点。</blockquote></p><p> Sales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.</p><p><blockquote>辉瑞治疗癌症和罕见病的药物以及主要用于医院的药物的销售额增长了两位数。本季度用于预防血栓和中风的Eliquis销售额增长16%至14.8亿美元，而Ibrance销售额增长4%至14亿美元。</blockquote></p><p> Pfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.</p><p><blockquote>辉瑞的肺炎疫苗Prevnar 13——迄今为止世界上最赚钱的疫苗——在疫情期间销售额增长了11%，达到12.4亿美元。该公司于6月获得了Prevnar 20的美国批准，这是一种针对成人的更新版本，可预防另外七种肺炎球菌疾病。</blockquote></p><p> In May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.</p><p><blockquote>5月，辉瑞和合作伙伴Myovent获得MyFembry的批准，用于减少绝经前妇女因子宫肌瘤导致的大量月经出血。</blockquote></p><p> Pfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US</p><p><blockquote>辉瑞的研究主管Mikel Dolstein概述了八个有可能对公共卫生产生重大影响的主要研究项目，包括治疗COVID-19的药丸以及每年都会发生的莱姆病和呼吸道合胞病毒的疫苗。感染并杀死超过5%的成年人。其中大约15,000人在美国</blockquote></p><p> Pfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.</p><p><blockquote>辉瑞目前预计调整后的全年收益将在每股3.95美元至4.05美元之间，高于5月份预期的每股3.55美元至3.65美元，营收将在780亿美元至800亿美元之间，从705亿美元增至725亿美元。</blockquote></p><p></p>","source":"lsy1627951004805","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer hikes 2021 outlook after vaccine boosts sales, profit<blockquote>疫苗提振销售和利润后辉瑞上调2021年展望</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer hikes 2021 outlook after vaccine boosts sales, profit<blockquote>疫苗提振销售和利润后辉瑞上调2021年展望</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Hala</strong><span class=\"h-time small\">2021-08-04 13:11</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Strong sales of its COVID-19 vaccine and other drugs helped<b> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.</p><p><blockquote>其COVID-19疫苗和其他药物的强劲销售有所帮助<b><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></b>第二季度营收增长近一倍，利润增长59%，超出华尔街预期。</blockquote></p><p> Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.</p><p><blockquote>其COVID-19疫苗和其他药物的强劲销售帮助辉瑞第二季度收入增长了近一倍，利润增长至59%，超出了华尔街的预期，并帮助这家制药巨头展望2021年。帮助快速提高了销售额和利润预测。</blockquote></p><p> Amid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.</p><p><blockquote>在日益严重的冠状病毒大流行中，COVID-19疫苗成为辉瑞最畅销的疫苗，创造了其近一半的收入——78.4亿美元来自直接销售和与其合作伙伴德国BioNTech的收入分成。</blockquote></p><p> Pfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US</p><p><blockquote>辉瑞目前预测，今年两剂疫苗的收入将达到335亿美元，其已签约在年底前提供21亿剂疫苗。这还不包括上周签署的向美国额外提供2亿剂疫苗的合同</blockquote></p><p> The New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.</p><p><blockquote>这家纽约公司周三透露，正在进行的一项在第二剂疫苗接种六个月后进行的加强注射试验表明，它将老年人和年轻人针对传染性更强的德尔塔变异毒株的抗体水平提高了11倍。增加了五倍多.,与两次给药后的水平相比。该公司还发布的数据显示，接种疫苗六个月后，疫苗在预防严重疾病方面的有效性为97%。</blockquote></p><p> “We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”</p><p><blockquote>首席执行官Albert Boerla在接受采访时表示：“我们绝对相信需要加强剂，第三剂原始疫苗可能就足够了。”尽管如此，辉瑞将在8月份开始在志愿者中测试针对Delta版本的加强剂，因为“利害攸关，你不能冒这个风险。”</blockquote></p><p> Bourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.</p><p><blockquote>Bourla表示，辉瑞已在全球交付了超过10亿剂疫苗，预计今年将生产30亿剂，其中更多将销往中低收入国家。到目前为止，欧洲和美国生产的所有新冠肺炎疫苗的大部分剂量都流向了富裕国家。</blockquote></p><p> By the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.</p><p><blockquote>到9月底，在5至11岁志愿者中进行的试验应产生在该年龄组中获得紧急使用授权所需的安全性和有效性数据，并应使用在6个月至5岁儿童中进行的试验数据。必须遵守。据辉瑞称，很快。</blockquote></p><p> The US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.</p><p><blockquote>美国食品和药物管理局目前正在审查可能导致成人疫苗完全批准的数据，Borla表示，这可能会减少接种疫苗的犹豫。</blockquote></p><p> Second-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.</p><p><blockquote>第二季度净利润为55.6亿美元，合每股98美分，高于34.9亿美元，合每股62美分。</blockquote></p><p> Adjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.</p><p><blockquote>不包括一次性损益的调整后收益为60.8亿美元，即每股1.07美元，明显高于华尔街的97美分。</blockquote></p><p> Its quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.</p><p><blockquote>其季度收入为189.8亿美元，高于去年的98.6亿美元，也超出了预期。</blockquote></p><p> Pfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.</p><p><blockquote>辉瑞股价上涨1.46美元，涨幅3.5%，至43.56美元，接近52周高点。</blockquote></p><p> Sales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.</p><p><blockquote>辉瑞治疗癌症和罕见病的药物以及主要用于医院的药物的销售额增长了两位数。本季度用于预防血栓和中风的Eliquis销售额增长16%至14.8亿美元，而Ibrance销售额增长4%至14亿美元。</blockquote></p><p> Pfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.</p><p><blockquote>辉瑞的肺炎疫苗Prevnar 13——迄今为止世界上最赚钱的疫苗——在疫情期间销售额增长了11%，达到12.4亿美元。该公司于6月获得了Prevnar 20的美国批准，这是一种针对成人的更新版本，可预防另外七种肺炎球菌疾病。</blockquote></p><p> In May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.</p><p><blockquote>5月，辉瑞和合作伙伴Myovent获得MyFembry的批准，用于减少绝经前妇女因子宫肌瘤导致的大量月经出血。</blockquote></p><p> Pfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US</p><p><blockquote>辉瑞的研究主管Mikel Dolstein概述了八个有可能对公共卫生产生重大影响的主要研究项目，包括治疗COVID-19的药丸以及每年都会发生的莱姆病和呼吸道合胞病毒的疫苗。感染并杀死超过5%的成年人。其中大约15,000人在美国</blockquote></p><p> Pfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.</p><p><blockquote>辉瑞目前预计调整后的全年收益将在每股3.95美元至4.05美元之间，高于5月份预期的每股3.55美元至3.65美元，营收将在780亿美元至800亿美元之间，从705亿美元增至725亿美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/\">Business Hala</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156524625","content_text":"Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.\n\nStrong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.\nAmid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.\nPfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US\nThe New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.\n“We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”\nBourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.\nBy the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.\nThe US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.\nSecond-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.\nAdjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.\nIts quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.\nPfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.\nSales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.\nPfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.\nIn May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.\nPfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US\nPfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":828,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/807705352"}
精彩评论